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Abbreviations 
FQs Fluoroquinolones, BBB Blood brain barrier, TdP Torsades de Pointes,  GI gastrointestinal tract, IC50 Half maximal 
Inhibitory concentration , MIC Minimum inhibitory concentrations, ZW zwitterion, steady state uptake (Rss), F blood plasma 
concentrations, CBP Chronic bacterial prostatis, BSA bovine serum albumin, MRP2 Multidrug resistance-associated protein 
2 or specific organic anion transporter 1 (cMOAT) or ATP-binding cassette sub-family C member 2 (ABCC2), OATP 
organic anion uptake transporter, OCT organic cation influx transporter, ΔGdesolvation free energy of water desolvation, 
ΔGlipophilicity  free energy of lipophilicity or hydrophobicity, ΔGdesolv,CDS  free energy of water desolvation of the cavitation 
dispersion solvent structure (CDS), ΔGlipo,CDS  free energy of lipophilicity or hydrophobicity for the CDS,  DM dipole 
moment DM,  SASA solvent accessible surface area, R2 multiple correlation coefficient, F the F test of significance, SEE 
standards errors for the estimates, SE(ΔGdesolvation) standard errors of ΔGdesolvation, SE(ΔGlipophilicity), standard errors of 
ΔGlipophilicity, SE(Dipole Moment) standard errors for dipole moments, SE (Molecular Volume) standard errors for molecular 
volumes as calculated from “t” distribution statistics, QM quantum mechanics, 
Introduction 
We have previously shown
1-5 
that four parameter equation (the general equation) can be 
successfully applied to: 
• the transport of drugs and physiologically important molecules across the blood brain 
barrier (BBB): passive (simple permeation and facilitated) diffusion  
• the competitive binding of statins to HMG CoA reductase 
• the passive and active competitive transport of statins by organic anion transporters 
• the competitive binding of a number of tyrosine kinase inhibitors and multi-kinase 
inhibitors to a range of kinase enzymes 
• the active competitive transport of these tyrosine kinase inhibitors by the hOCT3, 
OATP1A2 and OCT1 transporters 
• the binding of inhibitors to cyclin-dependent kinases (CDK) including multi-drug 
resistant CDK 
• the binding of inhibitors to HIV-1 proteases and poly(ADP-ribose) polymerases (PARP) 
• kinetic and equilibrium solubility in water of a large number of drugs 
• intestinal drug absorption of a large number of drugs: permeation and active transport 
• human intestinal permeation rates and human intestinal absorption for a large number of 
common drugs 
• Caco-2, PAMPA, Everted Gut Sac, Sartorius membrane  permeability of a large number 
of drugs 
• drug-MRP2 permeability interactions in Caco-2 cells have been evaluated by determining 
the A-to-B and B-to-A permeability of MRP2 inhibitors 
The model comprises four main drug properties calculated by quantum mechanical methods: 
(a) desolvation energy in water (b) lipophilicity or hydrophobicity based on the solvation 
energy in a hydrophobic solvent such as n-octane or n-octanol; lipophilicity being a measure 
of how well a drug can interact with lipophilic cell membrane bilayers, and hydrophobicity 
being a measure of non-polar interaction between a drug and the hydrophobic sectors of a 
protein (c) dipole moment in water, as a measure of the polar attraction between the drug and 
its receptor target or cell membrane  (d) the molecular volume of the drug in water as a 
measure of how well the prospective drug fits into the cavity of the target receptor protein or 
active protein transporter, or how well a drug can diffuse through a cell membrane.  
General Equation: 
Transport or Binding = ΔGdesolvation + ΔGlipophilicity + Dipole Moment + Molecular Volume  
Or 
Transport or Binding = ΔGdesolv,CDS + ΔGlipophilicity + Dipole Moment + Molecular Volume  
 
ΔGdesolvation = ΔGelectrostatic + ΔGCDS where CDS is the cavity dispersion solvent structure. The 
CDS involves non-bulk solvent electrostatic contributions to the free energy of hydration. 
The SMD solvation model is based on ΔGS
o  
=  ΔGENP + GCDS  where ENP is the electronic 
nuclear polarization: the change in the solute free energy due to electrostatic interactions 
between the solute and the bulk solvent and distortion of the solute’s electronic structure in 
solution. The solvent is modelled as a dielectric continuum. The CDS represents first 
solvation shell effects. It involves atomic surface tension (geometry dependent 
proportionality constants). The CDS has been parameterized using extensive experimental 
data sets for optimization, and has the advantage of including a realistic experimentally based 
hydrogen bonding model. The CDS covers shorter-range polarization effects and shorter-
range non-electrostatic effects such as cavitation, dispersion, and solvent structural effects 
(which includes both hydrogen bonding) and exchange repulsion effects.
6
 [Marenich 2009
6
] 
ΔGdesol,CDS can be substituted for ΔGdesolvation where this non-polar term may be more 
representative of the interaction processes being studied, as for example in a ligand-protein 
binding study within the protein binding pocket where the dielectric constant for that 
environment is ca. ε=7-10 compared to ε=78.3 for the bulk water environment where the use 
of ΔGdesolvation is more appropriate.
1,5,7,8
 [Fong 2016
1,5
,Rayne 2010
7
, Rizzo 2006
8
]  
 
When a solvated ligand enters a protein binding cavity and begins to bind with the protein, 
the desolvation processes involving the protein and ligand may involve extensive 
rearrangement of water molecules, and possibly some expulsion of water molecules from the 
cavity. A significant change in solvation entropy should then occur on the side on the ligand 
and the protein receptor. It is postulated that the ΔGdesolv,CDS values may be a close 
approximation of how a solvated inhibitor reacts as it approaches and starts to enter the 
binding pocket (dielectric constant ε=20-30) and leaves the bulk water environment (ε =78.3) 
and binding starts to occur (ε=7-10). This scenario has been modelled using more intensive 
molecular mechanics computations.
9,10,11
 [Setny 2010
9
, Shan 2010
10
, Mondial 2014
11
]  
 
A modified form of the general equation 1 using the free energy of water desolvation 
(ΔGdesolv,CDS) and the lipophilicity free energy (ΔGlipophilicity), where CDS represents the first 
solvation shell solvent properties, may be a good approximation of the drug approaching the 
entry of the protein receptor pocket or the surface of the protein transporter. Desolvation of 
water from the drug (ΔGdesolv,CDS) before binding in the receptor pocket is required, and 
hydrophobic interactions between the drug and protein (ΔGlipo,CDS) is a positive contribution 
to binding.  
 
In this study, the general equation will be applied to the critical steps as shown in Figure 1 as 
they affect the overall anti-bacterial and anti-malarial properties of the fluoroquinolones FQs, 
and the potential serious cardiac side effects of FQ-hERG induced QT prolongation and 
Torsades de Pointes (TdP) 
 
Figure 1. Flow chart of fluoroquinolone FQ processes involved in anti-bacterial or anti-
malarial therapy or serious side effects 
 
(a) FQ oral intake, dissolution, gastrointestinal fluid diffusion  
 
Oral administration is the most commonly used drug administration route. The ability to 
predict the rate and extent of absorption of candidate drugs after oral administration is crucial 
during the preclinical phase of development. Drug absorption from the gastrointestinal (GI) 
tract is affected by many factors, including the physiological conditions of the GI tract 
(including absorptive surface area, local pH, food effects, intestinal transit time, passive 
intestinal permeability) and the physio-chemical properties of the drug (including solubility, 
molecular size, polarity, lipophilicity, stability). Intestinal active drug transporters are also 
involved in controlling oral drug permeability and absorption. The drug intestinal 
permeability measure Peff is widely used indicator of both the rate and/or extent of drug 
absorption (Fa) in humans. A good correlation exists between the human jejunal permeability 
(Peff) measured using single-pass perfusion techniques and the fraction of dose absorbed from 
an immediate-release, rapidly dissolving drug.
12-15
 [Dahan 2012
12
, El-Kattan 2012
13
, Hou 
2006
14
, Waterbeemd 2003
15
] 
 
The solubility of orally administered drugs is a critical rate determining factor in determining 
bioavailability. FQs are generally fairly insoluble in water, with most modern FQs being 
zwitterionic, having both a carboxylic acid (pKa ~5.5-6.3) and basic amine group (pKa ~ 7.6-
9.3).  Minimum solubility is around the physiological pH ~ 7.4, where all concentrations of 
the cationic, neutral, anionic and zwitterionic species vary according to the pKa of the various 
FQs. The isoelectric point pI for many FQs is around 6.8-7.6 where the mole fractions of the 
neutral and zwitterionic species are maximal where their ratio is invariant and pH 
independent.
16-20
 [Sorgel 1993
16
, Liu
17
, Takacs-Novak 1990
18
, Ross 1992
19
, Zhang 2014
20
]  
We have previously shown that the general equation applies to a wide range of equilibrium 
and kinetic solubilities of drugs. These observed correlations are sensitive to the various 
charged, neutral and zwitterionic forms of drug species.
1-5
 [Fong 2015
1-5
]   
 
The lipophilicity of these FQs can vary according to the pH and pI points. As lipophilicity is 
a critical factor in drug discovery and pharmacology, the determination is critical. A common 
used method is logP (neutral species) or logD (ionic species) derived from water-octanol 
partitioning experiments. LogP measurements of FQ have been made
21
 [Takacs-Novak 1992] 
but a major criticism of logP partitioning is that n-octanol contains 2.8M water at 
equilibrium, a possible major error for sparingly soluble drugs. ΔGlipophilicity calculated from 
the solvation energy of the drug in n-octane (or n-octanol) is a better measure, and can be 
applied to neutral, ionized or zwitterionic species quickly and accurately.  
It has been concluded that MICs of FQs for E. coli (Gram negative) involved mainly neutral 
and zwitterionic forms (as well as cationic and anionic species). However since drug 
transport into Gram negative bacteria is dominated by porin transport, this result is not 
surprising. [Zhang 2014] In one study an amphoteric eburnane alkaloid, it was concluded that 
the zwitterionic form was the dominant form in membrane penetration because it was the 
dominant species present, despite the zwitterionic form having far lower lipophilicity (log D) 
than the neutral form (log P).
22
 [Mazak 2012] 
 
(b) FQ membrane permeation: uptake in blood and systemic circulation 
 
Passive membrane diffusion is comprised of two pathways: the paracellular pathway, where 
the drug diffuses through the aqueous pores at the tight junctions between the intestinal 
enterocytes, and the trans-cellular pathway, which requires the drug to permeate the cell 
membrane of the enterocyte. The paracellular pathway is thought to be important for 
intestinal transport of smaller (MW less than 250) and more hydrophilic drugs which are not 
repelled by the net negative charge of the junctional complex. The junctions only comprise 
0,01% of the surface area of the intestinal membrane, and become progressively tighter 
moving from the jejunam to the colon. Trans-cellular diffusion is thought to be the major 
transport pathway (mainly determined by transport across the apical cell membrane) for the 
uncharged (neutral) and more lipophilic drugs of MW > 300. The vast majority of drug 
molecules are transported through the transcellular pathway, and the few which rely on the 
paracellular pathway of transportation typically have a much lower bioavailability.
13
 [El-
Kattan 2012
13
] 
Active transport processes in enterocytes express several transporters, belonging to the 
adenosine triphosphate (ATP) binding cassette (ABC) superfamily and the solute carrier 
(SLC) superfamilies, on the apical and basolateral membranes for the influx or efflux of 
drugs.  
Drugs with a jejunal Peff  > 1.5 x 10
-4
 cm/s are completely absorbed independent of whether 
passive or active transport mechanisms are involved. Many drugs that are significantly 
effluxed in vitro have a rapid and complete intestinal absorption (>85%) mediated by passive 
transcellular diffusion. The jejunal Peff for drugs transported mainly by absorptive carriers 
(such as peptide and amino acid transporters) can predict the fraction of the dose absorbed as 
a consequence of the regional expression. The human intestinal epithelium has a large 
resistance towards large and hydrophilic compounds, and the paracellular route has a low 
contribution for compounds larger than approximately molecular weight 200.
23
 [Lannernas 
2007
23
] 
Caco-2 cell permeability is often used as a screening tool for assessing drug oral absorption 
during the early stages of drug development since these cells possess many structural and 
functional similarities to normal human enterocytes. Caco-2 permeability has generally 
correlated well with the fraction of the drug absorbed by the intestinal tissue for many drugs 
in humans. Caco-2 permeability is widely used as a surrogate for human intestinal 
permeability. Where active influx and efflux transporters are involved, the jujeunal 
permeability may sometimes still show a dependency with Fa but may show complex 
segmental permeability for low permeability drugs. Drugs with inherently high intestinal 
permeability are not affected by intestinal transporters.
12
 [Dahan 2012
12
] 
 
Most modern FQs have a high bioavailability, eg Ciprofloxacin 70%, Levofloxacin 99%, 
Moxifloxacin 86%, Gatifloxacin 95%, Norfloxacin 30-40%, Ofloxacin 98%. However, 
binding to blood serum proteins eg Ciprofloxacin 30%, Levofloxacin 31%, Moxifloxacin 
48%, Gatifloxacin 20%, Gemifloxacin 20% can reduce bioavailability, and methods to 
predict how new FQ will bind to serum proteins are useful during drug discovery. The 
negative effect of protein binding on antibiotic activity is well established, and other effects 
include lower elimination, lower glomerular filtration, volume of distribution and half life 
hence the lowering time above MIC.
24
 [Schmidt 2010
24
] 
 
(c) FQ transport across bacterial membranes 
 
The cell walls of gram-negative bacteria follow a more general structural format than that of 
gram-positive bacteria, which can vary considerably in different species. Gram negative 
bacteria possess a lipid-rich outer membrane (as well as a plasma membrane) and a thin 
peptidoglycan layer Gram-positive bacteria are enshrouded in thicker, more resilient cell 
walls and a thicker peptidoglycan layer in their cell wall.  
 
There are three major routes across the outer membrane: (a) the hydrophobic or bilayer 
pathway, involving the lipopolysaccahride LPS bilayer, (b) the self-promoted uptake pathway 
and (c) the hydrophilic or porin pathway involving the water filled trans-membrane proteins 
(porins).
25
 [Hancock 1997
25
] For most clinically used antibiotics the hydrophilic or porin 
pathway is more important. Studies on porins have shown that: (i) molecules of 500 Da and 
less diffuse easily through the outer membrane, and molecules up to 700 Da must be flexible 
to allow diffusion, (ii) the charge or hydrophilicity has a large effect, with neutral species 
diffusing fastest, cations generally diffusing faster than anions; multiple charged molecules 
diffusing even slower than single charged species; zwitterions diffused faster than anions (iii) 
there was an inverse relationship between lipophilicity (from log P partitioning) and diffusion 
rate.
26-30 
[Nikaido 1985
26
, Gunn 2001
27
, Hancock 1988
28
, Ma 1994
29
, Wiese 2003
30
] 
Mutations to the LPS bilayer can increase drug resistance. More importantly, porin deficiency 
has been associated with increased bacterial resistance in nearly all Gram-negative species 
involved in hospital-acquired infections.
31-34 
[Charrel 1996
31
, Yigit 2002
32
, Cornaglia 1995
33
, 
Domenech-Sanchez 2003
34] 
 
Resistance to fluoroquinolones can involve mutations of the target enzyme and changes to 
microbial cell permeability. Many Gram-negative bacteria contain genes for multiple efflux 
pumps, used by bacteria as secretion mechanisms for cellular products, and as defence 
mechanisms against harmful substances present in the environment. These efflux pumps also 
function as an active antibiotic accumulation barrier, by which a drug is pumped out faster 
than it can diffuse into the cell. The pumps include: the major facilitator superfamily (MFS), 
the ABC group, the resistance nodulation division family (RND), the multidrug- and toxic 
compound extrustion family (MATE), and the small (earlier staphylococcus) multidrug 
resistance (SMR) family. Of these the RND efflux pumps play the most important role in 
multidrug resistance in all Gram negatives bacteria. 
  
The MRP2 (or cMOAT or ABCC2) transporter is involved in drug disposition and 
distribution, particularly of organic anions and drug metabolites such as glucuronides.  MRP2 
is an efflux transporter that is important in drug biliary excretion and renal excretion, and also 
prevents xenobiotics from penetrating or accumulating in tissues such as lungs and from 
crossing the placenta. MRP2 is localized to the apical membrane domain of polarized cells 
such as hepatocytes, renal proximal tubule and intestinal epithelia, and is also present in the 
gallbladder, bronchi, and placenta. Multiple ABC transporters contribute to the overall active 
secretion of some fluoroquinolones (Grepafloxacin), and MRP2 has been demonstrated to 
mediate biliary excretion of some FQs.
35
 [Alvarez 2008
35
] 
 
(d) FQ anti-bacterial mechanism 
 
FQs kill bacteria by increasing levels of DNA strand breaks generated by type II 
topoisomerases. DNA topoisomerases are enzymes that control the topology of DNA in cells. 
Topoisomerases I and II are involved in the breakage of one or both strands of the DNA, and 
the passage of one segment of DNA through a break in another. Nearly all bacteria encode 
two type II topoisomerases, gyrase and topoisomerase IV. DNA gyrase (particularly in Gram 
negative bacteria) and topoisomerase IV (particularly in Gram positive bacteria) are primary 
targets for antibacterial agents, including the fluoroquinolones and the coumarins families. 
DNA gyrase is essential in all bacteria but is not found in humans, so it is an ideal target for 
antibacterials. The known reactions of topoisomerases include: relaxation and supercoiling, 
catenation and decatenation, knotting and unknotting. DNA supercoiling activity is unique to 
gyrase. 
 
It is well known that type II topoisomerases require divalent metal ions in order to cleave 
DNA.  Both type II enzymes are essential for cell survival. Fluoroquinolones (FQ) form a 
FQ-Topoisomerase II-DNA complex where the enzyme is trapped with the bound DNA. FQ 
can also form a complex with Topoisomerase IV utilizing a bridge between the ketone – 
carboxylate moiety of the FQ to a Mg ion linked to the serine and glutamate residues of the 
Topoisomerase IV, as shown in Figure 2.
36
 [Redgrave 2014
36
] A “water−metal ion bridge” 
acts as the primary conduit by which clinically relevant quinolones interact with 
topoisomerase IV. Mutations of the topoisomerase IV residues which form the {FQ-M
++
-
H2O-Topo IV} bridge are thought to be responsible for resistance to FQs.
37
 [Aldred 2014
37
]  
 
(e) Serious side effects of FQs 
The long QT syndrome (LQTS) is a disorder of ventricular repolarization that predisposes 
affected individuals to cardiac arrhythmia and sudden death. It has long been clinically 
recognized that drug-induced aLQTS is a serious side effect, and the cardiac hERG potassium 
channels have been related to this QT prolongation. Drugs such as terfenadine (Seldane)  
cisapride (Propulsid), grepafloxacin (Raxar) and terodiline block the hERG channel to 
deleterious effect and thus have been withdrawn from the market. Syncope, polymorphic 
ventricular tachycardia (torsade de pointes or TdP) and sudden cardiac death were 
particularly associated with terfenadine. Consequently, a hERG assay is now an 
indispensable step and a high-quality assay must accompany any investigational new drug 
(IND) application.
38
 [Brown 2004
38
] The nonclinical evaluation of the potential for delayed 
ventricular repolarization (QT interval prolongation) by human pharmaceuticals, issued as 
CHMP/ICH/423/02, was adopted by CHMP in May 2005. 
 
hERG encodes the pore-forming subunit of a delayed rectifier voltage gated K
+
 (VGK) 
channel. These channels are variously referred to as IKr, hERG, or Kv11.1 hERG forms the 
major portion of one of the ion channel proteins (the ‘rapid’ delayed rectifier current IKr) that 
conducts potassium (K
+
) ions out of the muscle cells of the heart, and this current is critical in 
correctly timing the return to the resting state (repolarization) of the cell membrane during the 
cardiac action potential. In the laboratory the heterologously expressed hERG potassium 
channel comprises 4 identical alpha subunits, which form the channel's pore through the 
plasma membrane. Each hERG subunit consists of 6 transmembrane alpha helices, numbered 
S1-S6, a pore helix situated between S5 and S6, and cytoplasmically located N- and C-
termini. The S4 helix contains a positively charged arginine or lysine amino acid residue at 
every 3rd position and is thought to act as a voltage-sensitive sensor, which allows the 
channel to respond to voltage changes by changing conformations between conducting and 
non-conducting states (called ‘gating’). This channel is also sensitive to drug binding, as well 
as decreased extracellular potassium levels, both of which can result in decreased channel 
function and drug-induced (acquired) long QT syndrome.
39
 [Vanderberg 2012
39
] 
Among the drugs that can cause QT prolongation, the more common ones include 
antiarrhythmics (especially Class 1A and Class III), anti-psychotic agents, and certain 
antibiotics (including quinolones and macrolides).
40,41 
[Briasoulis 2011
40
, Sanguinetti 2006
41
] 
Although there exist other potential targets for cardiac adverse effects, the vast majority of 
drugs associated with acquired QT prolongation are known to interact with the hERG 
potassium channel. One of the main reasons for this phenomenon is the larger inner vestibule 
of the hERG channel, thus providing more space for many different drug classes to bind and 
block this potassium channel.
42
 [Milnes 2003
42
]  
Fluoroquinolones prolong the QT interval by blocking voltage-gated potassium channels, 
especially the rapid component of the delayed rectifier potassium current IKr, expressed by 
hERG (the human ether-a-go-go-related gene). Moxifloxacin carries the greatest risk of QT 
prolongation from all available quinolones in clinical practice and it should be used with 
caution in patients with predisposing factors for Torsades de Pointes (TdP). Gemifloxacin, 
levofloxacin, and ofloxacin are associated with a lower risk of QT prolongation compared 
with Moxifloxacin, and Ciprofloxacin appears to be associated with the lowest risk for QT 
prolongation and the lowest TdP rate. The overall risk of TdP is small with the use of 
fluoroquinolones. Clinicians can minimize that risk by avoiding prescriptions of multiple 
medications associated with QT-interval prolongation, especially in high-risk patients.
40
 
[Briasoulis 2011
40
] 
Materials and methods: Experimental methods 
All calculations were carried out using the Gaussian 09 package at the B3LYP/6-31
 
G*(6d, 
7f)  level of theory with optimised geometries in water, as this level has been shown to give 
accurate electrostatic atomic charges, and was used to optimize the IEFPCM/SMD solvent 
model. With the 6-31G* basis set, the SMD model achieves mean unsigned errors of 0.6 - 1.0 
kcal/mol in the solvation free energies of tested neutrals and mean unsigned errors of 4 
kcal/mol on average for ions.
6
 [Marenich 2009
6
]The 6-31G** basis set has been used to 
calculate absolute free energies of solvation and compare these data with experimental results 
for more than 500 neutral and charged compounds. The calculated values were in good 
agreement with experimental results across a wide range of compounds.
7,8
 [Rayne 
2010
7
,Rizzo 2006
8
] Adding diffuse functions to the 6-31G* basis set (ie 6-31
+
G**) had no 
significant effect on the solvation energies with a difference of less than 1% observed in 
solvents, which is within the literature error range for the IEFPCM/SMD solvent model.
6
 
[Marenich 2009
6
] It is noted that high computational accuracy for each species in different 
environments is not the focus of this study, but comparative differences between various 
species is the aim of the study. The use of various literature values for Km, IC50 to develop the 
multiple regression equations have much higher uncertainties than the calculated molecular 
properties. The statistical analyses include the multiple correlation coefficient R
2
, the F test of 
significance, standards errors for the estimates (SEE) and each of the variables 
SE(ΔGdesolvation), SE(ΔGlipophilicity), SE(Dipole Moment), SE (Molecular Volume), 
SE(Molecular Volume), as calculated from “t” distribution statistics. Residual analysis was 
used to identify outliers. The solvation energies, lipophilicities, dipole moments, molecular 
volumes of the statins are shown in Table 2. 
 
It is noted that the various equations derived in this study are more indicative rather than 
highly robust in that statistical precision is taken as the goodness of fit (rather than extensive 
statistical validation) of the experimental data since insufficient experimental data are not 
available for highly robustly validated outcomes using the four independent variables. The 
correlations have used data from a single source where the experimental precision is 
consistent, as compared to using experimental data from multiple sources, where the 
interlaboratory experimental error can be very large, even for the same cell line, up to a factor 
of 10 as found by Aronov
63
. However the fact that the different biological processes in this 
study (Figure 1) are all well correlated by the general equation indicates that the general 
equation may a universally valid model for biological processes. 
 
Results 
Anti-bacterial properties of FQs 
Minimum inhibitory concentrations (MIC, μg/ml, DM4100 E. coli) for 17 FQ drugs: 
Sarafloxacin 0.086, Sparfloxacin 0.125, Fleroxacin 0.141, Orbifloxacin 0.150, Sitafloxacin 
0.015, Gemifloxacin 0.086, Grepafloxacin 0.016, Besifloxacin 0.100, Tosufloxacin 0.050, 
Lomefloxacin 0.172, Ulifloxacin 0.022, 8-Ethoxy-Moxifloxacin 0.200, Anthofloxacin 0.15, 
N-Methyl-Gatifloxacin 0.065, PD161144 0.096, Clinafloxacin 0.0095, Balofloxacin 0.484 all 
as zwitterionic species: [Schwanz 2012
43
]                                                Equation 1 
Log MIC =  - 0.049 ΔGdesolvation + 0.142 ΔGlipophilicity + 0.121 Dipole Moment + 0.009 
Molecular Volume + 0.902 
Where R2  = 0.624, SEE = 0.325, SE(ΔGdesolvation) = 0.030, SE(ΔGlipophilicity) = 0.073,  SE(Dipole Moment) = 0.062, 
SE(Molecular Volume) = 0.003, F = 5.0, Significance F = 0.013 
 
It is noted that treating the FQs as neutral species for the E.coli MICs gave a very poor 
correlation. 
Anti-malarial properties of FQs 
Plasmodium is a genus of parasitic protozoa, many of which cause malaria in their hosts. 
Antimalarial activities (IC50) of 20 quinolones and fluoroquinolones (Moxifloxacin, 
Lomefloxacin, Enoxacin, Norfloxacin, Grepafloxacin, Ciprofloxacin, Gatifloxacin, 
Clinifloxacin, Fleroxacin, Flumequine, Nalidixic Acid, Pipemidic Acid, Piromidic Acid, 
Chloroquine, Rufloxacin, Trovafloxacin (all as neutral species), Pefloxacin zwitterion (ZW), 
Sparflox (ZW), Levoflocacin (ZW), Ofloxacin (ZW) against chloroquine-sensitive (3D7) 
strains of Plasmodium falciparum in vitro [Mahmoudi 2003
44
]                            Equation 2 
IC50  =  4.96 ΔGdesolvation + 7.10 ΔGlipophilicity - 3.27 Dipole Moment - 0.26 Molecular 
Volume + 135.55 
Where R2  = 0.656, SEE = 20.18, SE(ΔGdesolvation) = 2.37, SE(ΔGlipophilicity) = 7.16,  SE(Dipole Moment) = 2.69, SE(Molecular 
Volume) = 0.23, F=7.16,  Significance F = 0.002, n=20 
 
Antimalarial activities (IC50) of 20 quinolones and fluoroquinolones (Moxifloxacin, 
Lomefloxacin, Enoxacin, Norfloxacin, Grepafloxacin, Ciprofloxacin, Gatifloxacin, 
Clinifloxacin, Fleroxacin, Flumequine, Nalidixic Acid, Pipemidic Acid, Piromidic Acid, 
Chloroquine, Rufloxacin, Trovafloxacin (all as neutral species), Pefloxacin zwitterion (ZW), 
Sparflox (ZW), Levoflocacin (ZW), Ofloxacin (ZW) against chloroquine-resistant (NF54-
R) strains of Plasmodium falciparum in vitro [Mahmoudi 2003
44
]                             Equation 
3 
IC50  =  2.42 ΔGdesolvation + 5.84 ΔGlipophilicity - 0.29 Dipole Moment - 0.06 Molecular 
Volume + 60.63 
Where R2  = 0.481, SEE = 17.53, SE(ΔGdesolvation) = 1.42, SE(ΔGlipophilicity) = 4.30,  SE(Dipole Moment) = 1.61, SE(Molecular 
Volume) = 0.14, F=3.47,  Significance F = 0.033, n=20 
 
The correlation equations for the 3D7 and NF54-R Plasmodium falciparum strains were very 
similar if Pefloxacin, Sparflox, Levoflocacin, and Ofloxacin were omitted as large outliers 
(R
2
 0.525, SE 28.65, F 2.77, F significance 0.087 for the 3D7 correlation, and R
2
 0.485, SE 
213.07, F 2.35, F significance 0.124 for the NF54-R correlation); however including these 
four FQs as the zwitterionic species gave the two equation 2 and 3 above which are better 
statistical correlations. This result shows that these correlations can differentiate between the 
neutral and zwitterionic forms of the FQs in their ability to inhibit Plasmodium falciparum 
strains. This observation strongly suggests that it is mainly the neutral form of the FQs that 
determines the overall efficacy against the Plasmodium falciparum strains, despite the many 
steps that must be involved in FQ pharmacokinetics for the FQ to achieve their anti-malarial 
efficacy.  
Antimalarial activities of 10 quinolones and fluoroquinolones (Norfloxacin,  Ciprofloxacin,  
Clinifloxacin, Piromidic Acid,  Rufloxacin, Trovafloxacin, Sparfloxacin (all as neutral 
species), Pefloxacin ZW,  Ofloxacin ZW, Grepafloxacin ZW) against hepatic stages of P. 
yoelii yoelii at 48 h. [Mahmoudi 2003
44
]                                       Equation 4                                                                                         
IC50  = 0.92 ΔGdesolvation – 5.32 ΔGlipophilicity - 4.56 Dipole Moment + 1.64 Molecular 
Volume - 288.26 
Where R2  = 0.756, SEE = 18.90, SE(ΔGdesolvation) = 2.25, SE(ΔGlipophilicity) = 6.17,  SE(Dipole Moment) = 2.64, SE(Molecular 
Volume) = 0.433, F=3.87,  Significance F = 0.085, n=10 
 
Antimalarial activities of 10 quinolones and fluoroquinolones (Norfloxacin,  Ciprofloxacin,  
Clinifloxacin, Piromidic Acid,  Rufloxacin, Trovafloxacin, Sparfloxacin (all as neutral 
species), Pefloxacin ZW,  Ofloxacin ZW, Grepafloxacin omitted) against hepatic stages of P. 
yoelii yoelii at 48 h. [Mahmoudi 2003
44
]                                    Equation 4a                                                       
IC50  = - 0.27 ΔGdesolvation – 8.28 ΔGlipophilicity - 3.96 Dipole Moment + 1.18 Molecular 
Volume - 288.26 
Where R2  = 0.767, SEE = 17.70, SE(ΔGdesolvation) = 2.30, SE(ΔGlipophilicity) = 6.21,  SE(Dipole Moment) = 2.52, SE(Molecular 
Volume) = 0.53, F=3.30,  Significance F = 0.137, n=9 
 
Comparison of eq 4 with eq 4a shows that by including Grepafloxacin (which showed the 
greatest effect against P. yoelii yoelii) as a zwitterion is a better statistical correlation than by 
simply omitting Grepafloxacin as an outlier from eq 4a. This outcome gives confidence that 
these correlations can distinguish amongst the zwitterionic and neutral forms of the various 
FQs in exerting their anti-malarial effect. 
 
Ring stage parasitized erythrocytes  were used for the 3D7 and NF54-R Plasmodium 
falciparum sudies. Mouse or human hepatocyte cultures were incubated for 24 h before 
sporozoite inoculation for the P. yoelii yoelii studies.
44
 [Mahmoudi 2003
44
] Comparison of 
eqs 2,3 with eq 4 show that the effect of the anti-malarials on the erythrocytes is very 
different from the effect on the hepatocytes with a large sensitivity on the lipophilicity and 
dipole moment (and lesser effect on the desolvation) for the hepatocytes. This observation is 
consistent with the more lipophilic environment in the liver tissue than for the red blood cells 
where a far more hydrophilic environment exists. 
  
Chronic bacterial prostatis (CBP) 
 
CBP is mainly caused by Gram-negative (and some Gram-positive) uropathogens, and FQs 
are the drugs of choice because of the favourable pharmacokinetics and anti-microbial 
spectrum. The concentrations of FQs in human seminal and prostatic fluids (and prostatic 
tissue) are important guides to efficacy of the FQs against CBP.
45
 [Weidner 2008
45
] The 
median concentrations in prostatic fluid:plasma ratios (normalized to a 400 mg dose) for 
Moxifloxacin, Lomefloxacin, Enoxacin, Norfloxacin, Ciprofloxacin, Gatifloxacin, 
Levofloxacin, Ofloxacin, all treated as neutral species (Fleroxacin omitted as outlier). All 
FQs were orally administered except Ciprofloxacin and Ofloxacin were IV.  Equation 5 
 
Prostatic fluid:plasma =  - 0.31 ΔGdesolvation - 0.27 ΔGlipophilicity + 0.21 Dipole Moment - 
0.01 Molecular Volume + 2.95 
Where R2  = 0.933, SEE = 0.21, SE(ΔGdesolvation) = 0.06, SE(ΔGlipophilicity) = 0.07,  SE(Dipole Moment) = 0.11, SE(Molecular 
Volume) = 0.01, F=10.52, Significance F = 0.041, n=8 
 
FQ uptake into rat brains and brain:blood plasma concentrations 
 
In vivo study of the steady state uptake (Rss) of FQ into rat brains and the ratio of brain to 
blood plasma concentrations (F) were determined for gatifloxacin, ofloxacin, ciprofloxacin, 
lomefloxacin, rufloxacin, pazufloxacin, norfloxacin, prulifloxacin, balofloxacin, 
caderofloxacin as neutral species, and sparfloxacin as the zwitterion. Sparfloxin was a clear 
outlier from the correlations with the neutral FQs, and omitting sparfloxacin or including it as 
a zwitterion gave similar statistical results. Treating all species as zwitterions gave a very 
poor correlation. [Liu 2005
46
]                                                                Equation 6 
 
Rss =  -12.1ΔGdesolvation – 31.2ΔGlipophilicity +12.5 Dipole Moment + 0.7 Molecular Volume – 
367.0 
Where R
2  
= 0.858, SEE = 88.9, SE(ΔGdesolvation) = 11.2, SE(ΔGlipophilicity) = 41.1,  SE(Dipole Moment) = 28.5, 
SE(Molecular Volume) = 1.9, F=9.05, Significance F = 0.010 
 
                                                                                                                Equation 7 
F = - 0.017ΔGdesolvation +0.010ΔGlipophilicity +0.040 Dipole Moment + 0.000 Molecular 
Volume – 367.0 
Where R
2  
= 0.754, SEE = 0.061, SE(ΔGdesolvation) = 0.007, SE(ΔGlipophilicity) = 0.028,  SE(Dipole Moment) = 
0.020, SE(Molecular Volume) = 0.001, F=4.59, Significance F = 0.048 
 
FQ oral intake, dissolution, gastrointestinal fluid diffusion 
Water solubility data (internally consistent very accurate equilibrium and kinetic solubility 
data base from the Goodman laboratory
47
) for 9 closely structurally related FQs was 
examined, ranging from Difloxacin 251.311 to  Danofloxacin 1260 μM for 8 drugs, but with 
a very high solubility (apparent outlier) for Oxfloxacin 54262.5 μM [Goodman
46
]. There was 
a good correlation when treating the drugs as neutral species, with Ofloxacin being a clear 
outlier unless treated as a zwitterion. Treating all FQs as zwitterions gave a fairly poor 
correlation R
2
 0.621, F significance 0.32). However, the best correlation was obtained when 
treating the drugs as anions, and Oxfloxocin as a zwitterion.  
 
Equilibrium solubility of 9 floxacins: Sarafloxacin, Norfloxacin, Difloxacin, Enrofloxacin, 
Lomefloxacin, Ciprofloxacin, Sparfloxacin, Danofloxacin treated as anionic species, 
Ofloxacin as zwitterion                                                                  Equation 8 
Log solubility = 0.054 ΔGsolvation + 0.270 ΔGlipophilicity + 0.165 Dipole Moment - 0.009 
Molecular Volume + 13.420 
Where R2  = 0.921, SEE = 0.293, SE(ΔGsolvation) = 0.062, SE(ΔGlipophilicity) = 0.115, SE(Dipole Moment) = 0.036, 
SE(Molecular Volume) = 0.005, F=11.61, Significance F = 0.018  
 
Equilibrium solubility of 9 floxacins: Sarafloxacin, Norfloxacin, Difloxacin, Enrofloxacin, 
Lomefloxacin, Ciprofloxacin, Sparfloxacin, Danofloxacin treated as neutral species, 
Ofloxacin as zwitterion                                                                  Equation 9 
Log solubility = 0.085 ΔGsolvation + 0.188 ΔGlipophilicity - 0.006 Dipole Moment - 0.009 
Molecular Volume + 5.684 
Where R2  = 0.838, SEE = 0.419, SE(ΔGsolvation) = 0.121, SE(ΔGlipophilicity) = 0.170, SE(Dipole Moment) = 0.172, 
SE(Molecular Volume) = 0.010, F5.56, Significance F = 0.070  
 Equilibrium solubility of 9 floxacins: Sarafloxacin, Norfloxacin, , Difloxacin, Enrofloxacin, 
Lomefloxacin, Ciprofloxacin, Sparfloxacin, Danofloxacin treated as anionic species, 
Ofloxacin as zwitterion,                                                                    Equation 10 
Log solubility = 0.035 ΔGCDS + 0.344 ΔGlipophilicity + 0.142 Dipole Moment - 0.007 
Molecular Volume + 11.512 
Where R2  = 0.914, SEE = 0.306, SE(ΔGsolvation) = 0.056, SE(ΔGlipophilicity) = 0.105, SE(Dipole Moment) = 0.026, 
SE(Molecular Volume) = 0.005, F=10.61, Significance F = 0.021  
 
Equations 11 and 12 show the same floxacin data analysed using kinetic solubility.
47
 
[Goodman] Kinetic solubility is the concentration of a compound in solution when an 
induced precipitate first appears, whereas equilibrium solubility is the concentration of 
compound in a saturated solution when excess solid is present, and solution and solid are at 
equilibrium. Kinetic solubility is commonly used in early drug discovery protocols. 
Equations 11 and 12 are very similar to those for eq 8,9 and 10. 
Kinetic solubility of 9 floxacins: Sarafloxacin, Norfloxacin, Difloxacin, Enrofloxacin, 
Lomefloxacin, Ciprofloxacin, Sparfloxacin, Danofloxacin treated as anionic species, 
Ofloxacin as zwitterion                                                                    Equation 11 
Log solubility = 0.053 ΔGsolvation + 0.226 ΔGlipophilicity + 0.130 Dipole Moment - 0.014 
Molecular Volume + 14.806 
Where R2  = 0.709, SEE = 0.524, SE(ΔGsolvation) = 0.111, SE(ΔGlipophilicity) = 0.206, SE(Dipole Moment) = 0.065, 
SE(Molecular Volume) = 0.009, Significance F = 0.204  
 
Kinetic solubility of 9 floxacins: Sarafloxacin, Norfloxacin, Difloxacin, Enrofloxacin, 
Lomefloxacin, Ciprofloxacin, Sparfloxacin, Danofloxacin treated as anionic species,  
Ofloxacin as zwitterion                                                                    Equation 12 
Log solubility = 0.167ΔGCDS + 0.372ΔGlipophilicity + 0.106Dipole Moment - 0.014 
Molecular Volume + 11.512 
Where R2  = 0.906, SEE = 0.299, SE(ΔGsolvation) = 0.056, SE(ΔGlipophilicity) = 0.102, SE(Dipole Moment) = 0.025, 
SE(Molecular Volume) = 0.004, Significance F = 0.025  
 
 
FQ human intestinal permeability, renal organic anion transporters, BBB permeability   
 
Avdeef
48
 and Wang
49
 have sought to calculate human jejunal permeability and absorption 
from  experimental Caco-2 data, assuming passive diffusion (transcellular and paracelloular). 
Intestinal Jejunal permeability Caco-2 pH 6.5 for 14 fluoroquinolones: Sarafloxacin, 
Norfloxacin, Ofloxacin, Difloxacin, Enrofloxacin, Lomefloxacin, Ciprofloxacin, 
Sparfloxacin, Danofloxacin, Gatifloxacin, Grepafloxacin, Pefloxacin, Flumequine, 
Moxifloxacin treated as neutral species. Log values are negative. Correlation with all FQ as 
ionic species was much worse F significance 0.604. Avdeef 2010
48
, Wang 2014
49
   Eq 13 
Log Caco-2 permeability = -0.274 ΔGdesolvation - 0.268 ΔGlipophilicity + 0.22 Dipole Moment - 
0.012 Molecular Volume - 2.450 
Where R2  = 0.600, SEE = 0.616, SE(ΔGsolvation) = 0.108, SE(ΔGlipophilicity) = 0.185, SE(Dipole Moment) = 0.126, 
SE(Molecular Volume) = 0.015, F=3.4, Significance F = 0.061  
 
Calculated human jejunal permeability rates (passive permeabilities 10
-4
 cm/s) from 
experimental Caco-2 values (pH 6.5), from Avdeef 2010
48
 and Wang 2014
49
 for the 14 FQ 
treated as neutrals species. Log permeabilities are negative values.          Equation 14 
Log calculated human permeability rates = -0.075 ΔGdesolvation - 0.107 ΔGlipophilicity + 0.059 
Dipole Moment - 0.004 Molecular Volume - 3.251 
Where R2  = 0.436, SEE = 0.243, SE(ΔGsolvation) = 0.042, SE(ΔGlipophilicity) = 0.073, SE(Dipole Moment) = 0.050, 
SE(Molecular Volume) = 0.006, F=1.75, Significance F = 0.225  
 
Since PAMPA membranes have no transporter capability, whereas Caco-2 membranes do 
have transporter capability, a comparison between PAMPA and Caco-2 transport of FQs may 
shed light on their intestinal permeability.  
 
PAMPA intrinsic permeability coefficients (Pe 10
−6
 cm/s) for the uncharged forms of  4′N-R-
norfloxacin: 0.7 (R=H), 49 (Me), 132 (n-Pr), 365 (n-Bu); 4′N-R-ciprofloxacin: 2.7 (H), 37 
(Me), 137 (n-Pr), 302 (n-Bu); 4′N-R-3′-methylciprofloxacin: 3.8 (H), 20 (Me), 51 (Et), 160 
(n-Pr), 418 (n-Bu). The alkyl chain length at the 4′N-position of the piperazine residue was 
varied as a function of pH from 4 to 10. Rat in situ permeability measurements were 
correlated with the PAMPA Pe measurements (r
2
=0.87).
50
 [Barmejo 2004
50
]  The substitution 
of various alkyl groups at the 4′N-position of the piperazine is related to a secondary FQ-
gyrase a binding mode that may overcome gyrase A mediated FQ resistence.
51
 [Malik 2016
51
]  
                                                                                                                   Equation 15 
Log PAMPA Pe = - 0.58ΔGdesolvation - 0.12ΔGlipophilicity -0.91Dipole Moment + 0.01 
Molecular Volume (Water) + 2.339 
Where R2  = 0.764, SEE = 0.52, SE(ΔGdesolvation) = 0.39, SE(ΔGlipophilicity) = 0.36,  SE(Dipole Moment) = 0.71, SE(Molecular 
Volume) = 0.005, F = 6.46, Significance F = 0.012 
                                                                                                                   Equation 16 
Log PAMPA Pe = 178.1ΔGdesol,CDS + 178.5ΔGlipophilicity -210.7Dipole Moment + 900.9 
Molecular Volume (Water) – 8305.2 
Where R2  = 0.856, SEE = 67.3, SE(ΔGdesolvation) = 84.1, SE(ΔGlipophilicity) = 76.4,  SE(Dipole Moment) = 47.8, SE(Molecular 
Volume) = 234.5, F = 11.85, Significance F = 0.002 
 
Transport of FQs by renally expressed basolateral SLC22 super family transporters: mOAT 
(mouse organic anion transporter mOAT3, active in adsorption and excretion of anions). 
Enoxacin, fleroxacin, levofloxacin, lomefloxacin, moxifloxacin, prulifloxacin, sparfloxacin*, 
norfloxacin, and ciprofloxacin* exhibit competitive inhibition for mOat3 with Ki = 396, 817, 
515, 539, 1356, 299, 205, 558 and 198 μM respectively.
52
 [Mulgaonkar 2012
52
]  A very poor 
correlation (R
2 
0.187, F significance 0.908) was obtained using the anionic FQ species, but 
Ciprofloxacin and Sparfloxacin were clear outliers. A better correlation was found using all 
species as zwitterions (R
2 
0.517, F significance 0.474), but again Ciprofloxacin and 
Sparfloxacin were clear outliers. Treating all species as zwitterions but with Ciprofloxacin* 
and Sparfloxacin* treated as anions gave a vastly improved correlation as shown below. 
 
Competitive basolatal renal inhibition of mOAT3 for 9 FQ drugs,
52
 [Mulgaonkar 2012
52
]  all 
drugs as zwitterionic species, or anionic species* (Ciprofloxacin*, Sparfloxacin*): Eq 17  
Log Ki =  -0.045 ΔGdesolvation - 0.007 ΔGlipophilicity + 0.052 Dipole Moment + 0.001 
Molecular Volume + 4.184 
Where R2  = 0.849, SEE = 0.149, SE(ΔGdesolvation) = 0.023, SE(ΔGlipophilicity) = 0.060,  SE(Dipole Moment) = 0.014, 
SE(Molecular Volume) = 0.002, F = 5.62, Significance F = 0.061 
 
Steady state in vitro competitive uptake of  
14
C Grepafloxacin in rat brain capillary 
endothelial cells in the presence of bicarbonate ions by 7 FQ drugs: Levofloxacin, 
Sparfloxacin, Nalidixic Acid as ionic species, Enofloxacin, Norfloxacin, Ofloxacin. 
Grepafloxacin as zwitterionic species: [Tamai 2000
53
]                                     Equation 18                                                                                       
Log Ki =  -0.009 ΔGdesolvation - 0.097 ΔGlipophilicity - 0.011 Dipole Moment - 0.004 Molecular 
Volume + 0.653 
Where R
2  
= 0.880, SEE = 0.100, SE(ΔGdesolvation) = 0.019, SE(ΔGlipophilicity) = 0.044,  SE(Dipole Moment) = 
0.010, SE(Molecular Volume) = 0.002, F=3.67, Significance F = 0.225 
 
The in vivo brain distribution of the FQ HSR-903 (Olamufloxacin), grepafloxacin and 
possibly other FQ were strongly influenced by efflux transporters, including P-gp at the BBB. 
The effect of 9 FQ on steady state uptake (%) of HSR-903 on in vitro primary-cultured 
monolayers of brain capillary endothelial cells was studied.  
 
Effect on in vitro brain capillary endothelial cell uptake of HSR-903 (Olamufloxacin) by the 
following FQs:  Grepafloxacin 360.5, Sparfloxacin 262.9, Levofloxacin 137.2, Tosufloxacin 
120.1, Lomefloxacin 137.0, Ofloxacin 130.5, Enoxacin 190.1, Norfloxacin 253.2, all neutral 
species, Nalidixic acid 50.9 was an outlier when treated as a neutral species, and gave an 
equally good correlation when omitted as an outlier or included as an ionic species. The 
correlation when treating all FQ species as zwitterions or ions was very poor. [Tamai and 
Tsuji 2000
54
]                                                                                          Equation 19 
Uptake % =  -46.45ΔGdesolvation – 5.14ΔGlipophilicity +150.95 Dipole Moment - 8.34 
Molecular Volume + 1389.1 
Where R
2  
= 0.925, SEE = 36.48, SE(ΔGdesolvation) = 7.90, SE(ΔGlipophilicity) = 11.87,  SE(Dipole Moment) = 
26.27, SE(Molecular Volume) = 1.56, F=12.4, Significance F = 0.015 
 
 
FQ binding to plasma proteins 
 
Bovine serum albumin BSA has been used as a proxy for human serum albumin – drug 
binding interactions. The binding constants for eight fluoroquinolone antibiotics 
(ciprofloxacin, enoxacin, fleroxacin, levofloxacin, lomefloxacin, norfloxacin, ofloxacin, 
pefloxacin) and bovine serum albumin (BSA) are known, (Kb 10
4
 M
-1
).
55
 [Liu 2006
55
] All 
FQs in zwitterionic form.  
                                                                                                                  Equation 20 
Kb  =  - 0.97 ΔGdesolvation - 2.50 ΔGlipophilicity - 0.74 Dipole Moment + 0.05 Molecular 
Volume + 35.55 
Where R2  = 0.943, SEE = 0.97, SE(ΔGdesolvation) = 0.23, SE(ΔGlipophilicity) = 0.58,  SE(Dipole Moment) = 0.44, SE(Molecular 
Volume) = 0.02, F=8.20,  Significance F = 0.111, n=8 
                                                                                                                 Equation 21 
Kb  =  - 0.95 ΔGdesol,CDS - 0.02 ΔGlipophilicity - 0.06 Dipole Moment - 0.002 Molecular 
Volume + 0.35 
Where R2  = 0.974, SEE = 0.55, SE(ΔGdesolvation) = 0.13, SE(ΔGlipophilicity) = 0.22  SE(Dipole Moment) = 0.25, SE(Molecular 
Volume) = 0.018, F=25.58,  Significance F = 0.010, n=8 
 
The correlations using the neutral forms of the FQs were very poor.  
FQ serious side effects: hERG cardiac QT prolongation 
 
Hagiwara 2001
56
 has assessed the effects of 10 fluoroquinolones on cardiac repolarization by 
measuring the action potentials recorded from isolated guinea pig right ventricular myocardia 
under constant conditions, namely, myocardial preparations were electrically stimulated at 
the fixed pacing frequency of 1 Hz. Sparfloxacin was the most active drug, at 10 μM, 
prolonged APD90  8.4%, and APD50 9.0%. All other drugs were measured at 100 μM as the 
APD90 values. Blockade of IKr  leads to a delay in the cardiac repolarization and prolongs the 
APD of myocardia and consequently prolongs the QT interval on the ECG. The action 
potential duration (APD90 100 μM) recorded from isolated guinea pig ventricular myocardia 
from ten fluoroquinolone antibacterial agents: Sparfloxacin 40.8, Moxifloxacin 25.1, 
Grepafloxacin 23.8, Gatifloxacin 12.7, Ciprofloxacin 3.3, Trovafloxacin 2.9, Levofloxacin 
0.8 (all as neutral species), Tosufloxacin ZW 5.2, Gemifloxacin ZW 4.2, Sitafloxacin  ZW 
2.4% [Hagiwara 2001
56
]                                                                                                     
                                                                                                        Equation 22 
APD90  = - 2.13 ΔGdesolvation – 7.80 ΔGlipophilicity - 1.29 Dipole Moment - 0.37 Molecular 
Volume - 288.26 
Where R2  = 0.611, SEE = 11.24, SE(ΔGdesolvation) = 1.51, SE(ΔGlipophilicity) = 4.08,  SE(Dipole Moment) = 1.38, SE(Molecular 
Volume) = 0.25, F=1.96,  Significance F = 0.238, n=10 
 
                                                                                                                                            Equation 23 
APD90  = 3.49 ΔGdesol,CDS – 4.26 ΔGlipophilicity - 3.23 Dipole Moment - 0.39 Molecular 
Volume - 288.26 
Where R2  = 0.735, SEE = 9.28, SE(ΔGdesolvation) = 1.52, SE(ΔGlipophilicity) = 1.75,  SE(Dipole Moment) = 1.17, SE(Molecular 
Volume) = 0.20, F=3.47,  Significance F = 0.101, n=10 
 
Kang 2001
57
 has examined the effect of FQs on chinese hamster ovary cells (CHO cells) 
transfected with cDNA encoding the hERG K1 channel cloned from a human neuroblastoma 
cell line. The inhibition (IC50 μM) of the hERG cardiac K
+
 channel by the FQs Sparfloxacin 
18, Moxifloxacin 129, Grepafloxacin 50, Gatifloxacin 130, Ciprofloxacin 966,  Levofloxacin 
815, Ofloxacin 1420 (as zwitterion) [Kang 2001
57
]                                  Equation 24 
 
IC50  = 210.47 ΔGdesolvation + 334.81 ΔGlipophilicity - 160.22 Dipole Moment + 17.71 
Molecular Volume - 1588.41 
Where R2  = 0.986, SEE = 116.61, SE(ΔGdesolvation) = 30.51, SE(ΔGlipophilicity) = 70.01,  SE(Dipole Moment) = 67.23, 
SE(Molecular Volume) = 3.15  F=35.21,  Significance F = 0.027, n=7 
 
The influence of the peak free plasma concentrations of the FQ on the IC50 values has also 
been investigated. The inhibition (IC50 μM/[Plasma]) of the hERG cardiac K
+
 channel by the 
FQs Sparfloxacin 18, Moxifloxacin 129, Grepafloxacin 50, Gatifloxacin 130, Ciprofloxacin 
966,  Levofloxacin 815, Ofloxacin 1420 (as zwitterion) [Kang 2001
57
]      Equation 25 
 
IC50 /[Plasma] = 17.35 ΔGdesolvation + 23.97 ΔGlipophilicity - 15.23 Dipole Moment + 1.24 
Molecular Volume - 1588.41 
Where R2  = 0.971, SEE = 14.30, SE(ΔGdesolvation) = 3.74, SE(ΔGlipophilicity) = 8.58,  SE(Dipole Moment) =8.24, SE(Molecular 
Volume) = 0.38  F=16.51,  Significance F = 0.057, n=7 
 
Eqs 24 and 25 using ΔGdesolvation where the IC50 values are corrected for the peak plasma 
concentrations of the FQs are very similar except the coefficients are roughly 12 times less 
sensitive for eq 25.  
The inhibition (IC50 μM) of the hERG cardiac K
+
 channel by the FQs Sparfloxacin 18, 
Moxifloxacin 129, Grepafloxacin 50, Gatifloxacin 130, Ciprofloxacin 966,  Levofloxacin 815 
(as Zwitterion), Ofloxacin 1420 (as zwitterion) [Kang 2001
57
]                   Equation 26 
 
IC50  = 140.64 ΔGdesol,CDS - 4.85 ΔGlipophilicity + 21.50 Dipole Moment + 0.49 Molecular 
Volume + 780.38 
Where R2  = 0.965, SEE = 183.91, SE(ΔGdesolvation) = 45.77, SE(ΔGlipophilicity) = 95.09,  SE(Dipole Moment) = 55.59, 
SE(Molecular Volume) = 7.04, F=13.86,  Significance F = 0.067, n=7 
 
The influence of the peak free plasma concentrations of the FQs on the IC50 values has also 
been investigated. The inhibition (IC50 μM/[Plasma]) of the hERG cardiac K
+
 channel by the 
FQs Sparfloxacin 18, Moxifloxacin 129, Grepafloxacin 50, Gatifloxacin 130, Ciprofloxacin 
966,  Levofloxacin 815 (as Zwitterion), Ofloxacin 1420 (as zwitterion) [Kang 2001
57
] Eq 27 
 
IC50 /[Plasma] = 13.07 ΔGdesol,CDS + 0.77 ΔGlipophilicity + 2.46 Dipole Moment + 0.13 
Molecular Volume + 70.48 
Where R
2  
= 0.966, SEE = 15.48, SE(ΔGdesolvation) = 3.85 SE(ΔGlipophilicity) = 8.00,  SE(Dipole Moment) = 4.68, 
SE(Molecular Volume) = 0.59, F=14.00,  Significance F = 0.068, n=7 
 
Eqs 26 and 27 using ΔGdesol,CDS where the IC50 values are corrected for the peak plasma 
concentrations of the FQs are very similar except the coefficients are roughly 11 times less 
sensitive for eq 27  
 
FQ anti-bacterial mechanism 
Inhibitory concentrations (IC50, μM, inhibition of gyrase supercoiling activity) for 12 FQ and 
Q drugs: Difloxacin, Enofloxacin, Norfloxacin, Pefloxacin. Ciprofloxacin, 8-Fluoro-
Ciprofloxacin, 8-Chloro-Ciprofloxacin, 8-Bromo-Ciprofloxacin, 8-Ethoxy-Ciprofloxacin, 
Oxalinic Acid, Piromidic Acid, Pipemidic Acid, as anionic species. (Ofloxacin was omitted 
as an outlier, which is consistent with Ofloxacin being a racemic mixture, with the S isomer 
having twice the anti-bacterail activity of the R isomer
58
 [Morrissey 1996
58
]). Ciprofloxacin 
and its 8-substituted derivatives, (8-F, 8-Cl, 8-Br, 8-Ethoxy) had the lowest IC50s (the most 
potent), and the nonfluorinated compounds oxolinic acid, pipemidic acid, and piromidic acid 
had the highest IC50s. [Noble 2003
59
]                                                  Equation 28                                                                                                              
Log IC50 =  - 0.007 ΔGdesolvation - 0.195 ΔGlipophilicity - 0.058 Dipole Moment - 0.014 
Molecular Volume - 0.816 
Where R2  = 0.753, SEE = 0.427, SE(ΔGdesolvation) = 0.056, SE(ΔGlipophilicity) = 0.093,  SE(Dipole Moment) = 0.089, 
SE(Molecular Volume) = 0.006, Significance F = 0.027 
 
                                                                                                                                                    Equation 29 
Log IC50 =  0.083 ΔGCDS - 0.217 ΔGlipophilicity - 0.100 Dipole Moment - 0.012 Molecular 
Volume - 0.821 
Where R2  = 0.801, SEE = 0.383, SE(ΔGCDS) = 0.064, SE(ΔGlipophilicity) = 0.067,  SE(Dipole Moment) = 0.048, SE(Molecular 
Volume) = 0.005, Significance F = 0.013 
 
The binding of FQ and Q drugs to 6-mer single stranded DNA oligonucleotides is correlated 
with potency IC50.
59
 [Noble 2003
59
] The binding (apparent KD) to ss-DNA for Difloxacin, 
Enofloxacin, Norfloxacin, Pefloxacin. Ciprofloxacin, 8-Fluoro-Ciprofloxacin, 8-Chloro-
Ciprofloxacin, 8-Bromo-Ciprofloxacin, 8-Ethoxy-Ciprofloxacin, Oxalinic Acid, as anionic 
species shows the following relationship   
                                                                                                                                                     Equation 30 
Log App KD =  0.050 ΔGCDS + 0.034 ΔGlipophilicity - 0.007 Dipole Moment + 0.013 
Molecular Volume + 4.067 
Where R2  = 0.704, SEE = 0.178, SE(ΔGCDS) = 0.030, SE(ΔGlipophilicity) = 0.040,  SE(Dipole Moment) = 0.002, SE(Molecular 
Volume) = 0.022, Significance F = 0.130 
 
Discussion 
 
FQ whole organism activity 
It has been shown that the general equation can describe the anti-bacterial (E. coli, eq 1) and 
anti-malarial activity (parasitic protozoa, Plasmodium falciparum, chloroquine-sensitive 3D7, 
eq 2) and  (Plasmodium falciparum, chloroquine-resistant NF54-R, eq 3). Plasmodium yoelii 
yoelii is also strongly correlated eq 4 and 4a.  
The essential difference between the FQ activity against the Plasmodium falciparum 
chloroquine-sensitive 3D7 strain and chloroquine-resistant NF54-R strain is a greater 
sensitivity to lipophilicity (and lesser sensitivity to desolvation and dipole moment) for the 
resistant strain. This may imply that hydrogen bonding and polar interactions are relatively 
reduced in resistant strains when bound to FQs (see discussion below on FQ mechanism).  
Ring stage parasitized erythrocytes  were used for the 3D7 and NF54-R Plasmodium 
falciparum sudies. Mouse or human hepatocyte cultures were sporozoite inoculations for the 
P. yoelii yoelii studies.
43
 [Mahmoudi 2003
43
] Comparison of eqs 2,3 with eq 4 show that the 
effect of the anti-malarials on the erythrocytes is very different from the effect on the 
hepatocytes with a large sensitivity on the lipophilicity and dipole moment (and lesser effect 
on the desolvation) for the hepatocytes. This observation is consistent with the more 
lipophilic environment in the liver tissue than for the red blood cells where a far more 
hydrophilic environment exists. 
 
Since the FQs can exist in various neutral, ionic or zwitterionic forms around the 
physiological pH, the correlations were tested against the various species, focussing on the 
strength of the correlations and using outlier analysis. It was shown that E. coli eq 1 gave a 
very poor correlation using neutral FQs, but a strong correlation using zwitterionic FQs. 
Siimilarly the Plasmodium correlations found that in eq 2 and 3 Pefloxacin, Sparfloxacin, 
Levoflocacin and Ofloxacin were far better correlated when treated as zwitterions, whereas 
the other 16 FQs were treated as neutral species. It appears that the general equation can 
differentiate amongst the various FQ species statistically, possibly indicating mechanistic 
differences within a species, and between different microbe families. 
 
The general equation also accurately describes the concentrations of FQs in human seminal 
and prostatic fluids (and prostatic tissue) ie the prostatic fluid:plasma in treating chronic 
bacterial prostatis, eq 5. All FQs were treated as the neutral species. 
 
The general equation also accurately describes the in vivo study of the steady state uptake 
(Rss) of FQs into rat brains and the ratio of brain to blood plasma concentrations (F) when 
treated as neutral species in eq 6 and 7.  
 
The overall results from eq 1-7 clearly demonstrate the general equation can successfully 
describe whole organism efficacy of FQs, as it applies to bacterial species, parasitic 
protozoa, humans and rats.  
 
FQ oral intake, dissolution, gastrointestinal fluid diffusion 
The rate determining step for movement of an orally ingested drug into the systematic blood 
system is the rate of dissolution. Oral Kinetic solubility is the concentration of a compound in 
solution when an induced precipitate first appears, whereas equilibrium solubility is the 
concentration of compound in a saturated solution when excess solid is present, and solution 
and solid are at equilibrium. Kinetic solubility is commonly used in early drug discovery 
protocols. Equations 11 and 12 for kinetic solubility are very similar to those for eqs 8,9 and 
10 which apply to equilibrium solubility. The best correlations for equilibrium solubility used 
FQs as the neutral or anionic species (with Ofloxacin as an zwitterion) whereas for kinetic 
solubility it was FQs in the anionic form which gave the better correlations (with Ofloxacin a 
zwitterion). Since FQs can exist as charged, neutral or zwitterionic forms at equilibrium at 
physiological pH, whereas kinetic dissolution requires the change from the solid state (with 
ionic lattice forces) to solution, these results are consistent with the experimental findings. It 
is also noted that a much more statistically rigorous analysis of over 70 common drugs also is 
well described by a similar equation to those in eqs 8-12.
5
 [Fong 2016
5
] 
 
FQ human intestinal permeability, renal organic anion transporters, BBB permeability   
 
It is widely considered that only neutral species can passively permeate cell membranes, 
cationic species may also permeate cell membranes, either by passive permeation or 
facilitated diffusion, but anionic species are widely considered not to passively permeate cell 
membranes. However, there are active transporters which can transport charged species 
across cell membranes of enterocytes, such as the ABC and SLC families.
13
 [El-Kattan 
2012
13
]     
Avdeef
48
 and Wang
49
 have calculated human jejunal permeability and absorption from  
experimental Caco-2 data, assuming passive diffusion (transcellular and paracellular) and 
have also calculated human jejunal permeability rates (passive permeabilities 10
-4
 cm/s). 
Strong correlations eq 13 and 14 have been found with their permeability data when treating 
the FQs as neutral species. 
The PAMPA intrinsic permeability coefficients for the uncharged forms of  4′N-R-
norfloxacin, 4′N-R-ciprofloxacin, and 4′N-R-3′-methylciprofloxacin (where R=H, Me, n-Pr, 
n-Bu) was strongly correlated in eq 15 and 16. As PAMPA permeation is purely passive 
permeation (unlike Caco-2 cells which have some active transporter capability), these 
equation show how large R substituents can affect the permeability. This is particularly 
shown in eq 16 where the molecular size coefficient is large compared to the other 
coefficients. This result reflects the use of ΔGCDS rather than ΔGsolvation in eq 16, which is the 
non-electrostatic contribution of ΔGsolvation and so reflects the non-polar contribution made the 
R substituents to the PAMPA cell permeation ie the relative contribution ΔGsolvation in eq 15 is 
larger than the relative contribution from ΔGCDS in eq 16, so emphasising the molecular 
volume contribution in eq 16. 
 
Eq 17 shows the transport of 9 FQs (mainly as zwitterions, but Ciprofloxacin and 
Sparfloxacin treated as anions) by renally expressed basolateral SLC22 super family 
transporters: mOAT (mouse organic anion transporter mOAT3, active in adsorption and 
excretion of anions). These data are known to include both influx and efflux of renal 
basolateral cells. The correlation for the active transporter is fairly strong, and the correlation 
with neutral or all anionic species was very poor.  
The steady state in vitro competitive uptake of  
14
C Grepafloxacin in rat brain capillary 
endothelial cells in the presence of bicarbonate ions by 7 FQ drugs (as anions) is shown in eq 
18. The effect on in vitro brain capillary endothelial cell competitive uptake of HSR-903 
(Olamufloxacin) by FQs (as neutral species) is shown in eq 19. Eq 18 is a relatively poor 
correlation possible reflecting the alkaline conditions and a dynamic equilibria of species. 
The in vitro data in Eq 19 more closely approximates the in vivo rat data of eq 6 where the 
pattern of coefficients are similar in relative magnitudes. 
FQ binding to plasma proteins 
 
Plasma protein binding PPB affects antibacterial efficacy for all antimicrobial classes, based 
on its effects on tissue penetration, elimination half-life and the volume of distribution. 
However PPB also impacts antimicrobial activity by reducing the available fraction of free 
drug. PPB leads to significant reduction of antimicrobial activity for moxifloxacin and 
trovafloxacin.
60
 [Zeitlinger 2008
60
] Plasma proteins are comprised of ca 55% serum albumin, 
globulins 38%, fibrogens 7% and the remainder are regulatory proteins. Eqs 20 and 21 show 
strong correlations with BSA binding using the zwitterionic forms of FQs.  The zwitterionic 
forms of the FQs are dominant at the physiological pH in blood plasma, and it is expected 
that binding interactions with the BSA would involve significant ionic and hydrogen bonding 
interactions. We have previously shown that correlations with ΔGdesolvation are more 
representative of the largely electrostatic bulk water environment (ε=78.3), whereas the 
correlations with ΔGdesol,CDS (which represents the non-polar solvation component of the 
interaction between the FQ solute and water), is more representative of the interior of the 
binding pocket of the BSA protein (ε=6-10). Eq 21 is dominated by the non-polar desolvation 
term, which largely determines binding strength between BSA and the FQs. 
FQ serious side effects: hERG cardiac QT prolongation 
                                                                                                                     
Hagiwara 2001
54
 has assessed the effects of 10 fluoroquinolones on cardiac repolarization by 
measuring the action potentials recorded from isolated guinea pig right ventricular myocardia 
tissue under constant conditions, namely, myocardial preparations were electrically 
stimulated at the fixed pacing frequency of 1 Hz. Sparfloxacin was the most active drug, at 10 
μM, prolonged APD90  8.4%, and APD50 9.0%. All other drugs were measured at 100 μM as 
the APD90 values. Blockade of IKr  leads to a delay in the cardiac repolarization and prolongs 
the APD of myocardia and consequently prolongs the QT interval on the ECG. The APD 
prolonging potency was sparfloxacin > moxifloxacin = grepafloxacin > gatifloxacin > 
tosufloxacin = gemifloxacin = ciprofloxacin = trovafloxacin = sitafloxacin = levofloxacin. 
This IKr  blockade order was the same found for rabbit and canine Purkinje fibers, as shown in 
Table 1.
61
 [Camm 2004
61
] This order closely approximates the order found by Kang 2001
55 
from inhibition of hERG channel currents using chinese hamster ovary cells (CHO cells) 
transfected with cDNA encoding the hERG K1 channel cloned from a human neuroblastoma 
cell line. These experimental results agree with clinical practice data which is that 
Moxifloxacin carries the highest risk of IKr  blockade (noting that Grepafloxacin was 
withdrawn from sale for causing adverse cardiac effects and that Sparfloxacin was also 
withdrawn from sale in most countries).   
 
  
 
Table 1. The effect of fluoroquinolones on IKr  blockade, action potential prolongation 
(ADP90), QT prolongation, and Torsades de Pointes (TdP). (Camm 2004) 
 
Eqs 22 and 23 show reasonably strong correlations for the ADP90 data when treating the FQs 
as neutral species (Tosufloxacin, Gemifloxacin, Sitafloxacin as zwitterions) with eq 23 being 
the more significant.   
 
Kang 2001
55
 has examined the effect of FQs on chinese hamster ovary cells (CHO cells) 
transfected with cDNA encoding the hERG K1 channel cloned from a human neuroblastoma 
cell line. Sparfloxacin was the most potent compound, IC50 18 μM, whereas ofloxacin was the 
least potent compound, IC50 1420 μM. QT prolongation observed clinically with 
administration of sparfloxacin and certain other fluoroquinolones showed a relationship with 
the free plasma levels after therapeutic doses was very similar to those concentrations that 
inhibit HERG channel current. However, levofloxacin, ciprofloxacin, and ofloxacin 
inhibition of HERG occurred at concentrations much greater than those observed clinically. It 
was concluded that clinically relevant hERG channel inhibition is not a class effect of the 
fluoroquinolone antibacterials but is highly dependent upon specific substitutions within this 
series of compounds. Eq 24 shows a good correlation with IC50 for the CHO cells which can 
be compared to eq 22 for the APD90 data from isolated guinea pig right ventricular myocardia 
tissue. The equations are similar but the signs of the independent variables are opposite, but 
the magnitudes are similar. 
Eqs 24 and 25 or 26 and 27 where the IC50 values are corrected for the peak plasma 
concentrations of the FQs are very similar except the coefficients are roughly 12 times less 
sensitive for eq 25 (compared to eq 24) and 11 times less sensitive for eq 27 (compared to eq 
26). These equations clearly show that the concentration inside the cells where activity occurs 
are lowered proportionally to the peak free plasma concentrations of the FQs. 
 
Ryu 2013
62
 have examined the binding modes of Levofloxacin and Sparfloxacin with the 
hERG channel which is a tetrameric protein and binds with a 1:1 stoichiometry. It was 
concluded that two Tyr652s in the neighbouring subunits and one or two Phe656s in the 
diagonal subunits contributed to the blockade in the case of both compounds, and Ser624 was 
also involved. Docking studies suggested that the protonated carboxyl group in the 
compounds strongly interacts with Phe656 as a π acceptor.  
 
Binding of drugs in the hERG channel has been previously considered to be dominated by: 
(a) hydrophobicity and or π-stacking interactions with Tyr652 and Phe656 on the S6 helix of 
the channel. Multiple aromatic or aromatic groups are critical for high affinity block. (b) 
flexibility to allow conformational change in the channel, (c) increasing the number of 
aromatic rings, (d) the presence of a charged amine group can (but not always) increase 
potency, (e) hydrophilic groups can decrease binding. The inhibitor orients itself along the 
pore axis, with the lipophilic end facing the opening to the cytosol and the polar tail facing 
the selectivity filter. One or two hydrophobic moieties interact with Phe656 side chains, 
probably via π-stacking(Figure 3). Multiple ligand binding sites exist on hERG that are 
capable of modulating channel activity. [Vanderburg 2012
39
, Aronov 2005
61
] 
 
Eqs 22-27 show that FQ binding to the tetrameric protein of the hERG channel is 
multifaceted, with desolvation of the FQ (and probably of the protein at Ser624) is critical as 
well as the hydrophobic interactions at Phe656s and Tyr652s, the dipole moment (as an 
indicator of polar interactions between the FQ and protein) and molecular sizes of the FQs. 
 
A major hurdle when constructing models using literature data has been the large discrepancy 
observed for hERG IC50 values determined in different laboratories. Inter-laboratory 
variability of greater than 10-fold is not uncommon, even in cases when inhibition was 
measured using the same cell line.
63
 [Aronov 2005
63
] This is generally true when assessing 
biological activity data for ligand drugs and particularly protein receptors, and using 
internally consistent data from the same sources has been found to be crucial in defining 
relationships where mechanistic conclusions are sought.
1-5
 [Fong 2015]  
 
FQ anti-bacterial mechanism 
The inhibition of gyrase supercoiling activity (IC50) by 12 FQ and Q drugs and the binding of 
FQ and Q drugs to 6-mer single stranded DNA oligonucleotides (apparent KD) has been 
analysed in eqs 28,29 and 30. The correlations with the non-electrostatic CDS values as 
opposed to the desolvation energy were superior, as shown in equation 29 and 30 as expected 
since non-electrostatic CDS correlations have been shown to better represent drug-protein 
binding within the binding pocket. Eqs 29 indicates that the potency of FQ inhibition of 
gyrase supercoiling activity is primarily dependent on lipophilicity and dipole moment of the 
FQ, with smaller but significant dependencies on desolvation and molecular volume. Eqs 30 
indicates that the potency of FQ binding to ssDNA is primarily dependent on desolvation and 
lipophilicity, with smaller but significant dependencies on dipole moment and molecular 
volume. 
 
  
 
Figure 2. Schematic representation of fluoroquinolone—Mg—Topoisomerase bridging 
interaction 
 
It has been proposed that one mode of resistance to fluoroquinolones may be associated with 
the magnesium ion water bridge to the bacterial type IV topoisomerases where the bridge is 
anchored to the serine and glutamic acid residues (Figure 2). The mechanism of quinolone 
resistance is suggested to be a result of serine mutations in the topoisomerase which causes 
partial loss of the Mg-H2O-topoisomerase bridge.
37
 [Aldred 2014
37
] The X-ray structures 
(PDB 2XKK) show the Moxifloxacin bond lengths C4=O 1.26A, chelated carboxyl C=O 
1.21A, C4=O—Mg 1.99A, carboxyl C=O—Mg 1.90A. The 4 water molecules octahedrally 
co-ordinated to Mg were set at 2.07A as per the X-ray structure (2XKK) and the separately 
characterised Mg(Ofloxacin)2 complex.
64,65 
[Wohlkonig 2010
64
, Dravensek 2006
65
] The 
hydrogen bonds between the serine O—H2O—Mg  and glutamic acid carboxylate C=O
--
—
H2O—Mg were arbitrarily varied from 2.60-3.0A  and 2.30-2.80A to reflect the weaker 
hydrogen bond to the serine residue and the ionic bridge to the glutamate carboxylate anion.  
 
The thermochemical analysis of the Moxifloxacin--Mg--(Serine, Glutamate) complex gave 
ΔG values (298K) for the MoxifloxacinMg to Serine,Glutamate interaction in the range of 
7.5-9.5 kcal/mol in water. The values are estimates only, as no account was taken of any 
wider topoisomerase interaction other than direct hydrogen and ionic bonding to the serine 
and glutamate residues, and the hydrogen bond lengths are not precisely known from the X-
ray structure. It is possible to compare these values with the thermodynamically derived 
complex interaction (using fluorescence emission spectroscopy) between DNA and several 
quinolones (Norfloxacin, Ciprofloxacin, and Ofloxacin) which gave ΔG values between 4.5 
and 5.5 kcal/mol.
66
 [Lee 2009
66
] It has been shown that the potency of a series of 
fluoroquinolones is related to the binding to 6-mer single stranded DNA oligonucleotides.
57
 
[Noble 2003
57
] The presence of the MoxifloxacinMg ion, and the glutamate ion, is expected 
to significantly increase the interaction with Serine/Glutamate residues of the topoisomerase 
compared to bare fluoroquinolones interacting with DNA. These data suggest that the Mg ion 
may play a significant role in fluoroquinolone activity through a fairly strong interaction with 
topoisomerase residues.  
 
The physiological bacterial concentration of free Mg
++
 is about 1-2 mM
67 
[Snavely 1990
67
], 
while the intracellular concentration of fluoroquinolone has been calculated to be 
~0.1mM.
68
[Lecomte 1994
68
] The binding constant for Mg(II) to ciprofloxacin is Ka = 
1.30x10
3
 M
-1
 [Lecomte 1994
68
] (the binding constant
69
 [Palu 1992
69
] for Mg
++
 to DNA is Ka 
= 22x10
3
 M
-1
). It can therefore be readily assumed that fluoroquinolones are complexed with 
Mg
++
 in the bacterial cell, though the equilibrium constants can vary with different 
fluoroquinolones and bacteria. 
 
These detailed mechanistic results are consistent with the findings from this study, in 
particular eqs 28,29 and 30 describing the inhibition of gyrase supercoiling activity and the 
binding to 6-mer single stranded DNA oligonucleotides. Desolvation of the FQs prior to 
protein binding is clearly a critical step that would be involved in establishing FQ-Mg-water-
Ser,Glu bridging.  
 
It is also noted above (eq 2,3) that the essential difference between the FQ activity against the 
Plasmodium falciparum chloroquine-sensitive 3D7 strain and chloroquine-resistant NF54-R 
strain is a greater sensitivity to lipophilicity (and lesser sensitivity to desolvation and dipole 
moment) for the resistant strain. This indicates that hydrogen bonding and polar interactions 
are relatively reduced in resistant strains when bound to FQs. Similarly desolvation has been 
shown to be the dominant factor influencing the effect of inhibitors against the cyclin-
dependent kinases, but lipophilicity and dipole moment are also significant factors in the 
resistance shown by MDR proteases to the anti-viral drugs.
1
 [Fong 2016
1
] 
 
 
 
 
 
 
Figure 3. Fluoroquinolone binding in the pore cavity of hERG channels. Solvated 
fluoroquinolone enters the channel, and partially desolvates prior to binding to channel 
proteins. Residues involved in fluoroquinolone binding possibly include Thr623, Ser624, and 
Val625 close to the intracellular entrance to the selectivity filter as well as two aromatic 
residues Tyr652 and Phe656. Open state only shown, but binding can possibly occur in 
inactived state. (adapted from Vanderberg 2012
39
) 
 
Conclusions  
 
It has been shown that the general equation can accurately describe the activity of FQs 
against whole organism anti-bacterial and anti-malarial parasites, the steady state uptake into 
rat brains, and the concentrations of FQs in human seminal and prostatic fluids (and prostatic 
tissue) when treating chronic bacterial prostatis. The reason that the general equation can 
describe whole organism effects is that many of the important individual pharmacological 
steps that contribute to such whole organism effects are also described by the same general 
equation.  
Desolvation / solvation effects have been shown to be an important (but usually overlooked) 
aspect of the most of the pharmacologically processes involved in FQ dissolution, intestinal 
permeation, systematic circulation, clearance, plasma protein binding, uptake and efflux into 
bacteria, binding to topoisomerases - DNA, and hERG QT prolongation. Most of these 
processes involve multi-faceted interactions amongst desolvation, lipophilicity, polar 
interaction and molecular size of the FQs and the environment, membrane, active anion 
membrane transporter, protein or hERG transport channel, or binding inhibitory interactions 
with gyrase supercoiling and 6-mer single stranded DNA oligonucleotides.   
 
Results from the study of sensitive and resistant strains of the malarial Plasmodium parasite 
show a greater sensitivity to lipophilicity (and lesser sensitivity to desolvation and dipole 
moment) for the resistant strain. This indicates that hydrogen bonding and polar interactions 
are relatively reduced in resistant strains when bound to FQs. This conclusion is supported by 
detailed binding free energies of the FQ-Mg-water-Ser,Glu bridging in type IV 
topoisomerases. 
 
It is also shown that serious side effects of FQs such as hERG QT prolongation can be 
predicted for new FQs. Another important conclusion that arises from this study is that the 
various neutral, ionic and zwitterionic species which can exist around the physiological pH 
can be differentially involved in the various processes.   
 
The general equation or its modified form is a useful guide to drug discovery and design, 
particularly the allowing examination of the various species of a potential drug that may 
predominate at different pH levels, or by making changes to the molecular structure to predict 
binding or transport properties.  
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Table 2. Solvation energies, lipophilicities, dipole moments and molecular volumes for 
fluoroquinolones, quinolones and related compounds 
Fluoroquinolones 
Quinolones 
ΔGsolvation 
kcal/mol 
(CDS) Water 
ΔGlipophilicity 
kcal/mol 
n-Octane 
Dipole 
Moment  
D Water 
Molecular 
Volume 
cm
3
/mol 
Water 
Moxifloxacin 
Moxifloxacin Zw 
Moxifloxacin Ion 
-19.5 (8.7) 
-109.7 (11.2) 
-90.1 (8.6) 
-15.4 
-44.0 
-38.2 
12.2 
62.9 
37.1 
262 
268 
305 
Lomefloxacin 
Lomefloxacin Zw 
Lomefloxacin Ion 
-16.2 (4.1) 
-103.0 (6.4) 
-82.3 (3.8) 
-10.3 
-39.4 
-31.8 
8.2 
56.8 
32.4 
210 
226 
233 
Enoxacin 
Enoxacin Zw 
Enoxacin Ion 
-21.1 (5.4) 
-109.2 (8.2) 
-91.7 (5.2) 
-14.3 
-42.5 
-37 
10.3 
56.4 
32.3 
225 
197 
212 
Norfloxacin 
Norfloxaci Ion 
Norfloxacin Zw 
-20.5 (1.8) 
-89.6 (1.5) 
-110.2 (4.6) 
-11.4 
-33.6 
-41.4 
10.8 
33.3 
57.9 
230 
189 
215 
Sparfloxacin 
Sparfloxacin Zw 
Sparfloxacin Ion 
-22.5 (8.0) 
-109 (10.2) 
-108.5 (7.9) 
-14.8 
-43.2 
-42.6 
13.7 
61 
58 
281 
255 
238 
Ofloxacin 
Ofloxacin Zw 
Ofloxacin Ion 
-20 (2.8) 
-102.7 (6.45) 
-87.8 (2.5) 
-12.1 
-39.7 
-33.9 
9.9 
57.8 
34.3 
224 
224 
275 
Grepafloxacin 
Grepafloxacin Zw 
Grepafloxacin Ion 
-19.6 (7.0) 
-108.2 (9.6) 
- 90.8 (6.9) 
-14.6 
-43.2 
-37.7 
12.8 
59 
35.2 
253 
201 
270 
Ciprofloxacin 
Ciprofloxacin Zw 
Ciprofloxacin Ion 
-20.6 (1.9) 
-110.0 (4.6) 
-89.6 (1.6) 
-12.4 
-42.5 
-34.7 
10.6 
57.7 
32.9 
226 
184 
245 
Gatifloxacin 
Gatifloxacin ZW 
Gatifloxacin Ion 
-19.8 (8.6) 
-108.2 (11.25) 
-91.1 (8.5) 
-14.2 
-42.9 
-37.4 
13.5 
59.4 
36.6 
251 
219 
233 
Danofloxacin 
Danofloxacin Ion 
-18.9 (1.7) 
-85 (1.45) 
-12.7 
-34.2 
7.1 
31.4 
205 
218 
Sarafloxacin 
Sarafloxacin ZW 
Sarafloxacin Ion 
-18.5 (4.4) 
-106.8 (7.1) 
-86 (4.7) 
-13 
-42.8 
-34.7 
9.5 
57.1 
33.3 
248 
257 
259 
Pefloxacin 
Pefloxacin Zw 
Pefloxacin Ion 
-19.9 (6.4) 
-109 (9.5) 
-91.2 (6.3) 
-13.8 
-43.2 
-36.9 
13.8 
61 
36.9 
249 
255 
210 
Flumequine 
Flumequine Ion 
-12.5 (5.6) 
-82.6 (5.3) 
-9.8 
-32.4 
10.6 
27.4 
185 
196 
Fleroxacin 
Fleroxacin Zw 
Fleroxacin Ion 
-19 (7.6) 
-104.9 (10.6) 
-86.4 (7.5) 
-13.1 
-41.8 
-35 
10.9 
59.1 
34.9 
225 
223 
227 
Levofloxacin 
Levofloxacin Zw 
Levofloxacin Ion 
-22.5 (6.8) 
-108.5 (10.2) 
-94.9 (6.7) 
-14.8 
-42.6 
-38.2 
13.7 
58 
35.8 
281 
238 
259 
Prulifloxacin 
Prulifloxacin Zw 
Prulifloxacin Ion 
-28.9 (10.6) 
-117.3 (13.4) 
-96.6 (10.5) 
-19 
-46.0 
-40.5 
18.3 
62.1 
45.4 
284 
283 
308 
Chlorequine -10.15 (2.45) -11.5 5.93 356 
Clinifloxacin -18.7 (8.0) -13.9 12.1 254 
Rufloxacin -20.4 (2.2) -12.9 9.3 233 
Trovafloxacin -21.8 (11.65) -14.35 20.3 249 
Tosufloxacin 
Tosufloxacin Zw 
-18.6 (9.1) 
-111.5 (10.7) 
-14.5 
-44.3 
10.6 
59 
251 
250 
Gemifloxacin 
Gemifloxacin Zw 
-23.5 (8.9) 
-111.7 (10.3) 
-16 
-45.5 
9.9 
64.9 
220 
250 
Sitafloxacin 
Sitafloxacin Zw 
-18.9 (8.1) 
-111.0 (9.3) 
-14.5 
-46.3 
10.4 
60.2 
254 
239 
Enrofloxacin  
Enrofloxacin Ion 
- 21.1 (1.88) 
-88.4 (1.9) 
-13.2 
-35.4 
10.3 
35.6 
224 
211 
Difloxacin 
Difloxacin Ion 
-17.8 (4.3) 
-85.2 (3.97) 
-13.2 
-34.8 
9.2 
34.3 
266 
262 
Pipemidic Acid -21.4 (-0.25) -13 7.4 241 
Nalidixic Acid -15.9 (4.9) -9.7 7.1 176 
Piromidic Acid -18.2 (1.9) -13.6 8.6 212 
Olamfloxacin 
Olamfloxacin Ion 
-19.1 (8.8) 
-90.8 (8.7) 
-14.4 
-37.5 
10.2 
34.8 
270 
267 
Orbifloxacin  
Orbifloxacin Zw 
-19.2 (8.1) 
-107.6 (10.2) 
-13.7 
-41.8 
11.2 
59.9 
254 
257 
     
 
 
 
 
 
